tafolecimab
innovent biologics
['ibi306', 'tafolecimab', 'innovent', 'imab ']
innovent releases results of a phase 3 clinical study of tafolecimab ibi306 in chinese patients with non- familial hypercholesterolemia at the american heart association (aha) scirntific sessions 2022 
To develop and commercialize high-quality biopharmaceuticals that are affordable to ordinary people.